![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Netherlands-based DSM Hit by Chinese Competition
Netherlands-based DSM Hit by Chinese Competition
Royal DSM NV, the leading Netherlands-based vitamins producer, has claimed that Chinese competition has led to a deterioration in results for its anti-infective pharmaceuticals business. The company has also cited government moves that have led to an oversupply of Penicillin G in China.
DSM recently entered discussions with leading Chinese drugmaker North China Pharmaceuticals Corporation, reportedly with a view to obtaining a US$25mn stake in the company's anti-infectives output. The move is intended to ensure competitiveness with low-cost rivals, which are a feature of the more basic end of the Chinese market.
The group, which has reported a 66 percent rise in operating profit to EUR489mn (US$638.73mn) for 2004, has also acquired Swiss drugmaker Roche's minority stake in a Shanghai-based vitamins joint venture, following its purchase of Roche's nutritional products business in 2003.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct